WASHINGTON — The trade association for generic drugs and biosimilars has chosen a new leader: John Murphy.
Four sources familiar with the decision said Murphy will be named as the new head of the Association for Accessible Medicines. AAM declined to comment on the CEO selection, but a spokesperson for the group said it will make an announcement later Wednesday.
Murphy was the chief policy officer at the Biotechnology Innovation Organization before being laid off in May, along with dozens of others, in a major reorganization under BIO’s new CEO. Murphy had been at BIO for more than seven years before he departed. Prior to that, he served as an assistant general counsel at the brand drug lobby PhRMA and in state government relations during a prior stint at BIO.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
